Concordia International Corp

CXR-T

TSE:CXR

25.04
0.39 (1.53%)
Concordia Healthcare Corp is a publicly traded pharmaceutical company based in Canada. The company focuses on Attention-Deficit Hyperactivity Disorder, cancer and asthma.
More at Wikipedia

Analysis and Opinions about CXR-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
September 7, 2018

Likes turnarounds, but it’s not ready. Want to see two things: 1) the stock hitting a 52-week high, and 2) the numbers moving in the right direction. Don’t do anything until then. Odds are this is going to zero.

Show full opinionHide full opinion

Likes turnarounds, but it’s not ready. Want to see two things: 1) the stock hitting a 52-week high, and 2) the numbers moving in the right direction. Don’t do anything until then. Odds are this is going to zero.

DON'T BUY
DON'T BUY
May 7, 2018

They are going through a restructuring, which is a codeword for bankruptcy. It is in the purely speculative category. There is nothing here for common shareholders.

Show full opinionHide full opinion

They are going through a restructuring, which is a codeword for bankruptcy. It is in the purely speculative category. There is nothing here for common shareholders.

WATCH
WATCH
November 16, 2017

You likely can’t salvage anything from here. If you are interested in this stock then wait for it to have a couple of positive quarters and let the chart be your guide.

Show full opinionHide full opinion

You likely can’t salvage anything from here. If you are interested in this stock then wait for it to have a couple of positive quarters and let the chart be your guide.

BUY
BUY
November 13, 2017

It is a very Canadian story. They are a drug manufacturer that were hit in a wave that took down others. He does not follow it closely, but a number of these stories have the ability to reconstitute themselves. They can find a way to make money at it or find someone to take them over.

Show full opinionHide full opinion

It is a very Canadian story. They are a drug manufacturer that were hit in a wave that took down others. He does not follow it closely, but a number of these stories have the ability to reconstitute themselves. They can find a way to make money at it or find someone to take them over.

SELL
SELL
October 18, 2017

It has lost the overwhelming majority of its value. It is burdened with leverage. It is important to step back and take a cold, clinical view of it. The market does not care what you paid for it. The prospects going forward don’t look very favourable for it. The subordinate debt went into default this week. The stock is more of a lottery ticket.

Show full opinionHide full opinion

It has lost the overwhelming majority of its value. It is burdened with leverage. It is important to step back and take a cold, clinical view of it. The market does not care what you paid for it. The prospects going forward don’t look very favourable for it. The subordinate debt went into default this week. The stock is more of a lottery ticket.

DON'T BUY
DON'T BUY
October 11, 2017

She wouldn’t be buying this now, even though the stock price has come down dramatically from what it was a few years ago. This has only been public for about 4-5 years, and they’ve been buying assets. There is a lot of pricing pressure on the drugs they bought and paid a lot for. Has a lot of debt on their balance sheet. Debt to Enterprise EBITDA is over 11X. There is a big question as to how they are going to repay the debt when it comes due. Based on what they have now, it doesn’t seem sufficient.

Show full opinionHide full opinion

She wouldn’t be buying this now, even though the stock price has come down dramatically from what it was a few years ago. This has only been public for about 4-5 years, and they’ve been buying assets. There is a lot of pricing pressure on the drugs they bought and paid a lot for. Has a lot of debt on their balance sheet. Debt to Enterprise EBITDA is over 11X. There is a big question as to how they are going to repay the debt when it comes due. Based on what they have now, it doesn’t seem sufficient.

WAIT
WAIT
October 5, 2017

He loves turnaround stories with lots of debt. When you get them right, they really move. This one is not a turnaround yet. It has a lot of things that you look for, what it doesn’t have are signs of a turnaround. Wait until you see two quarters of deleveraging and improving margins. The stock will move from there. It still has bankruptcy risks.

Show full opinionHide full opinion

He loves turnaround stories with lots of debt. When you get them right, they really move. This one is not a turnaround yet. It has a lot of things that you look for, what it doesn’t have are signs of a turnaround. Wait until you see two quarters of deleveraging and improving margins. The stock will move from there. It still has bankruptcy risks.

PAST TOP PICK
PAST TOP PICK
September 20, 2017

(A Top Pick June 21/16. Down 95%.) He sold this before the end of last year.

Show full opinionHide full opinion

(A Top Pick June 21/16. Down 95%.) He sold this before the end of last year.

DON'T BUY
DON'T BUY
September 12, 2017

Doesn’t think this is investable. Net debt to EBITDA is about 11X, which is very high. They have absolutely no visibility in terms of pricing in the UK, because the whole pricing regime is changing. She can’t see how they are going to pay the debt which comes due in 2021.

Show full opinionHide full opinion

Doesn’t think this is investable. Net debt to EBITDA is about 11X, which is very high. They have absolutely no visibility in terms of pricing in the UK, because the whole pricing regime is changing. She can’t see how they are going to pay the debt which comes due in 2021.

COMMENT
COMMENT
June 23, 2017

He is pessimistic on this. They recently hired another set of advisors to advise them on capital structure. That usually doesn’t end well for equity holders. Just had so much debt. The big UK acquisition they made really went south on them in a hurry. Expects debt holders are either going to want a massive equity dilution or for some kind of bankruptcy and restructuring. The equity is probably close to worthless.

Show full opinionHide full opinion

He is pessimistic on this. They recently hired another set of advisors to advise them on capital structure. That usually doesn’t end well for equity holders. Just had so much debt. The big UK acquisition they made really went south on them in a hurry. Expects debt holders are either going to want a massive equity dilution or for some kind of bankruptcy and restructuring. The equity is probably close to worthless.

COMMENT
COMMENT
May 9, 2017

This as not an investable name. They borrowed money to make a UK acquisition and are having issues with that.

Show full opinionHide full opinion

This as not an investable name. They borrowed money to make a UK acquisition and are having issues with that.

PAST TOP PICK
PAST TOP PICK
April 11, 2017

(A Top Pick March 3/16. Down 95%.) About 9 months ago, he advised his members that it was time to move on from this name.

Show full opinionHide full opinion

(A Top Pick March 3/16. Down 95%.) About 9 months ago, he advised his members that it was time to move on from this name.

DON'T BUY
DON'T BUY
February 23, 2017

Technically it has fallen off the face of the earth. You are making a gamble at this point. He would not move into healthcare at this time of the year.

Show full opinionHide full opinion

Technically it has fallen off the face of the earth. You are making a gamble at this point. He would not move into healthcare at this time of the year.

COMMENT
COMMENT
February 22, 2017

If looking to be exposed to all the positive attributes about global healthcare, this is not a company he would be focusing on.

Show full opinionHide full opinion

If looking to be exposed to all the positive attributes about global healthcare, this is not a company he would be focusing on.

DON'T BUY
DON'T BUY
February 1, 2017

Concordia (CXR-T) or Valeant (VRX-T)? He wouldn’t pick either because whenever you have accounting irregularities, that never gets better, especially in Canada. This sector is under so much heat right now. The US president has really focused in on even legitimate drug companies and there is going to be a lot of scrutiny. doesn’t think either will survive.

Show full opinionHide full opinion

Concordia (CXR-T) or Valeant (VRX-T)? He wouldn’t pick either because whenever you have accounting irregularities, that never gets better, especially in Canada. This sector is under so much heat right now. The US president has really focused in on even legitimate drug companies and there is going to be a lot of scrutiny. doesn’t think either will survive.

Showing 1 to 15 of 204 entries

Concordia International Corp(CXR-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Concordia International Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Concordia International Corp(CXR-T) Frequently Asked Questions

What is Concordia International Corp stock symbol?

Concordia International Corp is a Canadian stock, trading under the symbol CXR-T on the Toronto Stock Exchange (CXR-CT). It is usually referred to as TSX:CXR or CXR-T

Is Concordia International Corp a buy or a sell?

In the last year, there was no coverage of Concordia International Corp published on Stockchase.

Is Concordia International Corp a good investment or a top pick?

Concordia International Corp was recommended as a Top Pick by Fabrice Taylor on 2018-09-07. Read the latest stock experts ratings for Concordia International Corp.

Why is Concordia International Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Concordia International Corp worth watching?

0 stock analyst on Stockchase covered Concordia International Corp In the last year. It is a trending stock that is worth watching.

What is Concordia International Corp stock price?

On 2018-12-01, Concordia International Corp (CXR-T) stock closed at a price of $25.04.